MedStar Health Advances in Urologic Oncology 2024

Friday, November 1, 2024, 7:30 AM - Saturday, November 2, 2024, 3:00 PM, Bethesda Marriott, Bethesda, MD

Registration is closed and will re-open onsite November 1, 2024 at the Bethesda Marriott, Bethesda, MD.

 

The MedStar Health Advances in Urologic Oncology 2024 conference is a comprehensive educational event designed for healthcare professionals involved in the diagnosis, treatment, and management of urologic cancers. This conference will cover the latest advancements in the field, focusing on prostate, bladder, kidney, and testicular cancers. Attendees will gain in-depth knowledge of cutting-edge research, emerging therapies, and innovative treatment approaches through a series of lectures, panel discussions, and keynote presentations from leading experts.

Prostate Cancer: The prostate cancer sessions will provide an in-depth look at the latest advancements in the diagnosis, treatment, and management of this prevalent disease. Discussions will include advanced imaging techniques, such as PSMA PET imaging and multiparametric MRI, which have revolutionized the detection and staging of prostate cancer. Emerging techniques in transperineal biopsy will be highlighted for their benefits in reducing infection risks and improving diagnostic accuracy. Genomic testing is increasingly crucial in guiding treatment decisions, and the conference will explore the evolving role of genomic classifiers like Decipher, particularly in identifying candidates for active surveillance and tailoring treatment plans based on individual genetic profiles. Additionally, the latest advancements in systemic therapy, including androgen receptor inhibitors and chemotherapy, will be examined for their effectiveness in treating advanced and metastatic prostate cancer. Key trials such as ENZAMET, TITAN, and ARCHES will be discussed to highlight the benefits of novel hormonal agents in improving survival outcomes. Strategies for managing castration-resistant prostate cancer (CRPC) will be discussed, focusing on new agents such as lutetium Lu 177 vipivotide and their role in targeting metastatic disease. The VISION trial will be reviewed for its significant findings on the efficacy of PSMA-targeted radioligand therapy in CRPC. A dedicated session on the management of active surveillance patients will explore best practices for monitoring and decision-making, ensuring that patients receive the most appropriate care based on their individual risk profiles and disease progression. This will include a discussion of the ProtecT trial outcomes, which demonstrated the safety and efficacy of active surveillance in low-risk prostate cancer, and the role of MRI and genomic testing in surveillance protocols.

Kidney Cancer: Kidney cancer, particularly renal cell carcinoma (RCC), presents significant challenges in both diagnosis and treatment. The conference will delve into the evolving guidelines on partial versus radical nephrectomy and the role of cytoreductive nephrectomy in the treatment landscape. Recent advancements in systemic therapies, including immune checkpoint inhibitors and targeted therapies, will be highlighted, with a focus on key clinical trials such as CheckMate 214, which established the combination of nivolumab and ipilimumab as a first-line treatment for advanced RCC, and KEYNOTE-426, which showed the benefits of pembrolizumab plus axitinib. Comprehensive strategies for managing metastatic RCC will be discussed, including the use of combination therapies and the latest research on biomarkers for treatment selection. The conference will review the PROBE trial, which is investigating the role of cytoreductive nephrectomy in the context of immune checkpoint-based combination therapies. Attendees will gain insights into the latest advances in adjuvant therapy, with a review of the KEYNOTE-564 trial demonstrating the efficacy of pembrolizumab in the adjuvant setting for high-risk RCC patients.

Bladder Cancer: Bladder cancer management has seen significant advancements with the introduction of novel intravesical therapies and systemic treatments. The conference will provide clarity on treatment strategies for non-muscle invasive bladder cancer (NMIBC), including alternatives for BCG-naive and BCG-resistant disease. Emerging therapies for advanced bladder cancer will be discussed, along with the role of blue light cystoscopy in enhancing cancer detection and management. Updates on the use of immune checkpoint inhibitors and combination therapies for metastatic bladder cancer will be provided, with a focus on key trials such as IMvigor130, which evaluated atezolizumab in combination with chemotherapy, and the DANUBE trial, which assessed durvalumab with or without tremelimumab. Comprehensive strategies for managing advanced bladder cancer will be explored, including real-world applications of new treatments and their impact on patient outcomes.

Testicular Cancer: Testicular cancers, though less common, require specialized diagnostic and treatment approaches. The conference will highlight advances in diagnostic techniques, including the role of miRNA profiling and other biomarkers in early detection. Innovations in robotic-assisted surgery for lymph node dissection and retroperitoneal lymph node dissection (RPLND) will be discussed. Emerging systemic treatment options for metastatic and advanced testicular cancer will be covered, with an emphasis on the role of platinum-based chemotherapy and novel targeted therapies. The conference will review key clinical trials and provide comprehensive strategies for managing advanced penile and testicular cancers, incorporating the latest data on novel therapies and their efficacy.

Multidisciplinary Care: The integration of multidisciplinary care is essential for optimizing patient outcomes in urologic oncology. The conference will explore best practices for integrating care across specialties, ensuring a collaborative approach to patient management. Strategies to address and mitigate disparities in urologic oncology, focusing on the social determinants of health, will also be discussed.

1. Prostate Cancer Diagnosis and Imaging: Describe the role of advanced imaging techniques in diagnosing prostate cancer, including applying PSMA imaging and TP biopsy methods.
2. Innovations in Testicular Cancer: Explore recent advances in diagnostics, including miRNA, and evaluate the role of surgical interventions such as RPLND and robotic ILND in managing testicular cancers.
3. Genetic and Biomarker Considerations: Evaluate the current and emerging genetic and biomarker tools for assessing prostate cancer risk and their implications for personalized treatment plans.
4. Localized Prostate Cancer Treatment Options: Compare the efficacy and suitability of focal therapy, surgical options, and radiation in the treatment of localized prostate cancer.
5. Management of Metastatic Prostate Cancer: Discuss the latest approaches in the systemic treatment of metastatic prostate cancer, including novel pharmacologic therapies and management strategies.
6. Complex Case Discussion: Analyze the management strategies for conventional imaging negative, PSMA-positive prostate cancer patients through expert panel discussions.
7. Kidney Cancer Management: Identify the latest diagnostic techniques and their impact on surgical and systemic treatment strategies for renal cell carcinoma.
8. Role of Adjuvant Therapy in Kidney Cancer: Discuss the implications of recent clinical trials (e.g., KEYNOTE) on using adjuvant therapy in renal cell carcinoma.
9. Bladder Cancer Therapeutics: Assess treatment strategies for high-grade non-muscle invasive bladder cancer (HG NMIBC), including alternatives to BCG and management of BCG-resistant disease.
10. Interdisciplinary Approach in Urologic Oncology: Integrate interdisciplinary approaches and collaborative strategies in treating urologic cancers, enhancing patient-centered care across various disease states.
11. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with urologic malignancies.

Early Bird Now thru September 8th

Physician: $125  
Resident and Fellow: Complimentary No Fee 
Physician Assistant: $50  
Nurse Practitioner: $50  
Nurse: $50  
Allied Health Professional: $50
Medical Student: Complimentary No Fee 
Industry Professional: $200
1-Day Pass: $75

September 8th - November 2

Physician: $150  
Resident and Fellow: Complimentary No Fee 
Physician Assistant: $75 
Nurse Practitioner: $75 
Nurse: $75
Allied Health Professional: $75
Medical Student: Complimentary No Fee 
Industry Professional: $225
1-Day Pass: $90

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Designation Statement:

  

This activity was planned by and for the healthcare team and learners will receive 11.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Surgery CC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC Participation Threshold
Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 11.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

 

AMA PRA Category 1 Credits™ Physician (11.75 hours), ABIM MOC Part 2 (11.75 hours), ABS CC (11.75 hours), IPCE (11.75 hours), Non-Physician Member of the Healthcare Team (11.75 hours), Nurse - ANCC (11.75 hours)

The registration form for this activity is currently unavailable.

 

Bethesda Marriott
5151 Pooks Hill Road
Bethesda, MD 20814
(301)897-9400

Hotel Website

If you are interested in supporting the program, please contact Elizabeth Romano at Elizabeth.S.Romano@medstar.net